Biomea Fusion Quote - BMEA

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

2.84

Bid

2.80

Offer

2.94

Volume

694,134

2.78 Day's Range 2.96

2.80 52 Week Range 19.3549

Market Cap

102.918M

Previous Close

2.84

Open

2.95

Last Trade

2.82

Last Trade Time

10:09:13

Financial Volume

US$ 1,988,987

VWAP

2.8654

Average Volume (3m)

798,646

Shares Outstanding

36,238,687

Dividend Yield

PE Ratio

-0.87

Earnings Per Share (EPS)

-3.24

Revenue

Net Profit

-117.26M

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.biomeafusion.com

Headquarters

Wilmington, Delaware, USA

Founded

Biomea Fusion Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BMEA. The last closing price for Biomea Fusion was US$2.84. Over the last year, Biomea Fusion shares have traded in a share price range of US$ 2.80 to US$ 19.3549.

Biomea Fusion currently has 36,238,687 shares in issue. The market capitalisation of Biomea Fusion is US$102.92 million. Biomea Fusion has a price to earnings ratio (PE ratio) of -0.87.

Form 8-K - Current report

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea...

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide...

Form S-8 - Securities to be offered to employees in employee benefit plans

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a...

Form 8-K - Current report

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean...

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a...

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to...

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.75	-20.8913649025	3.59	3.75	2.8	522149	3.12444117	CS
4	-1.4	-33.0188679245	4.24	4.43	2.8	470720	3.60838601	CS
12	-4.11	-59.1366906475	6.95	7.06	2.8	798646	4.32122644	CS
26	-4.98	-63.6828644501	7.82	13.07	2.8	777289	6.95044329	CS
52	-13.17	-82.2610868207	16.01	19.3549	2.8	971101	8.41684215	CS
156	-3.93	-58.0502215657	6.77	43.69	2.8	667907	14.32552366	CS
260	-17.16	-85.8	20	43.69	2.8	549835	14.19481092	CS

BMEA - Frequently Asked Questions (FAQ)

What is the current Biomea Fusion share price?

The current share price of Biomea Fusion is US$ 2.84

How many Biomea Fusion shares are in issue?

Biomea Fusion has 36,238,687 shares in issue

What is the market cap of Biomea Fusion?

The market capitalisation of Biomea Fusion is USD 102.92M

What is the 1 year trading range for Biomea Fusion share price?

Biomea Fusion has traded in the range of US$ 2.80 to US$ 19.3549 during the past year

What is the PE ratio of Biomea Fusion?

The price to earnings ratio of Biomea Fusion is -0.87

What is the reporting currency for Biomea Fusion?

Biomea Fusion reports financial results in USD

What is the latest annual profit for Biomea Fusion?

The latest annual profit of Biomea Fusion is USD -117.26M

What is the registered address of Biomea Fusion?

The registered address for Biomea Fusion is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Biomea Fusion website address?

The website address for Biomea Fusion is www.biomeafusion.com

Which industry sector does Biomea Fusion operate in?

Biomea Fusion operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ULYUrgent ly Inc	US$ 0.8301 (97.64%)	6.18M
CPOPPop Culture Group Company Ltd	US$ 1.33 (92.20%)	9.26M
BLMZBloomZ Inc	US$ 0.49 (36.19%)	6.85M
NIXXNixxy Inc	US$ 2.11 (33.54%)	7.87M
ROOTRoot Inc	US$ 116.00 (17.52%)	114.53k
DMRCDigimarc Corporation	US$ 20.00 (-26.04%)	38.97k
SYTASiyata Mobile Inc	US$ 3.18 (-23.74%)	493.31k
SPGCSacks Parente Golf Inc	US$ 0.58 (-20.78%)	1.46M
TNDMTandem Diabetes Care Inc	US$ 27.3999 (-18.43%)	309.99k
PITAHeramba Electric PLC	US$ 0.5655 (-17.86%)	1.51M
NVDANVIDIA Corporation	US$ 130.03 (-0.95%)	40.91M
CPOPPop Culture Group Company Ltd	US$ 1.33 (92.20%)	9.26M
NIXXNixxy Inc	US$ 2.11 (33.54%)	7.87M
CLEUChina Liberal Education Holdings Ltd	US$ 0.063 (-15.21%)	7.09M
BLMZBloomZ Inc	US$ 0.49 (36.19%)	6.85M